New review highlights the complexity of treating cognitive aspects of DMD
One-third of individuals with DMD experience cognitive or behavioral differences, but treating DMD’s impact on the brain poses challenges.
News
-
-
Study finds postural control clearly declines in patients with DMD over a one-year period
Patients with DMD significantly lose postural control over a relatively short span of time.
-
Review explores delivery of DMD therapies to the central nervous system
New RNA-based treatments show promise for improving brain symptoms in DMD by reaching the central nervous system.
-
Diagnosing DMD before symptoms appear may mean better motor function later
Physicians should aim to diagnose DMD as early as possible.
-
Dyne Therapeutics receives Breakthrough Therapy designation for DYNE-251
DYNE-251, developed by Dyne Therapeutics and aimed at treating DMD, has received a Breakthrough Therapy Designation.
-
Report highlights disconnect between young patients and caregivers
A new report reveals a communication gap between young people with rare diseases and their caregivers in preparing for adulthood.
-
New study shows blocking RNA molecule could boost muscle repair in DMD
A mouse study suggests that blocking microRNA-33 may one day help reduce muscle damage in people with Duchenne muscular dystrophy
-
Precision BioSciences receives FDA Orphan Drug Designation for PBGENE-DMD
Precision BioSciences has announced that PBGENE-DMD has received FDA Orphan Drug Designation.
-
People with DMD want more inclusive sex education, study finds
People with Duchenne muscular dystrophy (DMD) and similar conditions want more inclusive sexual education that meets their unique needs.
-
Researchers expand hope for DMD while grappling with setbacks
Advances in gene and small molecule therapies offer new hope for Duchenne muscular dystrophy, but no cure currently exists.
